The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Point-Based Calculations for Premiums Will Improve Predictability, Says Creator
May 1, 2014
-
BUSINESS Takeda, Teva to Commercialize Teva’s Parkinson’s Disease Treatment Rasagiline in Japan
April 30, 2014
-
ACADEMIA Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
-
REGULATORY MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
-
REGULATORY Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
-
BUSINESS MTPC Names Masayuki Mitsuka as New President
April 24, 2014
-
BUSINESS Astellas Aims to Dominate SGLT-2 Inhibitor Market with Suglat
April 23, 2014
-
BUSINESS Lilly Japan Starts PIII Study of Tadalafil for DMD Treatment
April 22, 2014
-
REGULATORY MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
April 21, 2014
-
REGULATORY New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn
April 18, 2014
-
REGULATORY Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear
April 18, 2014
-
BUSINESS Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
-
REGULATORY Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
April 17, 2014
-
BUSINESS Metal Found in Voltaren Product Again: Novartis
April 17, 2014
-
ORGANIZATION Funding for Investigator-Led Studies Should Be Based on Contracts: EFPIA Japan
April 16, 2014
-
BUSINESS FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
-
BUSINESS Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
-
ACADEMIA Public Hospitals Seeking to Avert Penalty Fee Cuts for Low Price Settlements
April 14, 2014
-
BUSINESS 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
-
REGULATORY Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
April 10, 2014
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…